Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1649 1675 1678
This examiner grants 54% of resolved cases
Stacey Nee Macfarlane serves as an examiner in Tech Center 1600 and Art Unit 1645. The examiner has handled 839 resolved cases. The allowance rate for these 839 resolved cases is 53.5 percent. This 53.5 percent rate provides a clear indication of the likelihood of securing a patent grant in Art Unit 1645. The median days to allowance for this examiner is 1223, which is the time typically required to reach a successful outcome.
The interview lift is 39.6 percent. This 39.6 percent lift indicates that conducting an interview is associated with an increased probability of allowance. For practitioners, this positive lift suggests that direct communication with the examiner in Tech Center 1600 can be a beneficial strategy. The 1223 median days to allowance reflects the duration of the prosecution process for successful applications.
With 839 resolved cases, the data offers a reliable basis for strategy development. The 53.5 percent allowance rate and the 39.6 percent interview lift are important for evaluating the potential success of an application. Practitioners can use the 1223-day median to advise clients on the expected timeline. These figures provide a comprehensive view of the examiner's historical performance in Art Unit 1645.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18521870 | UNIVERSAL SENSING SYSTEM | Non-Final OA | Abbott Diabetes Care, Inc |
| 18429055 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | Non-Final OA | Genentech, Inc. |
| 18039403 | METHODS AND MATERIALS FOR TREATING T CELL CANCERS | Non-Final OA | The Johns Hopkins University |
| 18284750 | Bispecific Molecules and Related Compositions and Methods | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18546141 | LOW INTENSITY ULTRASOUND COMBINATION CANCER THERAPIES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18558689 | ELECTROPHYSIOLOGICAL MODIFICATION TO SUPPRESS ARRHYTHMIAS | Non-Final OA | UNIVERSITY OF WASHINGTON |
| 18269099 | ANTIGEN-BINDING MOLECULES WITH IMPROVED CYTOSOL-PENETRATING ACTIVITY | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17345248 | INTEGRATED DRUG DISCOVERY PLATFORM FOR INBORN ERROR OF METABOLISM DISORDERS | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18474419 | Use of Biomarkers in the Treatment of Fibrotic Conditions with a PDE4B-inhibitor | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18054285 | Compositions Comprising Human Skin Fibroblasts and Amyloid Beta Peptide | Final Rejection | WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY |
| 17914598 | BETA-ARRESTIN COMPOSITIONS AND ASSOCIATED METHODS | Final Rejection | Duke University |
| 18017841 | PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS | Final Rejection | City of Hope |
| 17426627 | MULTISPECIFIC BINDING PROTEINS | Non-Final OA | Gritstone bio, Inc. |
| 17066961 | FIBROBLAST GROWTH PATTERNS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE | Final Rejection | WEST VIRGINIA UNIVERSITY |
| 18021211 | METHOD FOR DIAGNOSING AND TREATING COGNITIVE IMPAIRMENT AND USE THEREOF | Non-Final OA | BAO FENG BIOTECH (BEIJING) CO., LTD |
| 17961412 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND ASSESSING RHEUMATOID ARTHRITIS USING PROTEIN-ARGININE DEIMINASE 1 (PAD1) AUTOANTIGENS | Non-Final OA | INOVA DIAGNOSTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy